News | October 13, 2022
Evonik and Phathom Pharmaceuticals partner to produce novel acid-blocker vonoprazan
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
Agreement strengthens Evonik’s track record as leading contract development and manufacturing organization (CDMO)
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
The Congress was held on June, 20-21, 2022 in Berlin, Germany
The Congress gathers pharmaceutical companies, CMOs and CDMOs, governmental bodies together with pharmaceutical equipment providers and service companies
John served as General Manager for Catalent Pharma Solutions in St. Petersburg, Florida
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
He will be responsible for the company's overall strategy and provide the necessary direction and dynamic leadership to R&D, manufacturing, business development, and commercial operations
He will be stationed at the company HQ in Bengaluru, India
The facility is expected to be completed in 2024
Subscribe To Our Newsletter & Stay Updated
